Personalised healthcare (PHC) has awakened many hopes among physicians and patients. Therapies that are tailored to individual patients and their particular illnesses facilitate a more precise, safe and efficient form of care. But personalised medicine is just getting started. This edition of Compass highlights the opportunities and describes the limitations of personalised treatment. It also delves into the hopes and fears associated with this medical advance. Articles written by scientific and industrial experts explore these opportunities and limitations from a medical, economic and patient-related perspective. A survey of 200 oncologists, pathologists and health insurers in the United States, Great Britain and Germany reflects the current status of information and discussions. At the same time, it points the way to future developments.
Personalised healthcare (PHC) has awakened many hopes among physicians and patients. Therapies that are tailored to individual patients and their particular illnesses facilitate a more precise, safe and efficient form of care. But personalised medicine is just getting started. This edition of Compass highlights the opportunities and describes the limitations of personalised treatment. It also delves into the hopes and fears associated with this medical advance. Articles written by scientific and industrial experts explore these opportunities and limitations from a medical, economic and patient-related perspective. A survey of 200 oncologists, pathologists and health insurers in the United States, Great Britain and Germany reflects the current status of information and discussions. At the same time, it points the way to future developments.
Annika Dröge
Arzneimittelforschung Diagnostische Forschung Molecular medicine Personalised Healthcare Personalisierte Medizin Pharmacodynamics Pharmacogenetics Pharmacogenomics Pharmacotherapy Pharmakodynamik Pharmakogenetik Pharmakotherapie